Bibliography
- Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;330:1289-91
- Umbrain V, Christiaens F, Cann F. Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994;8:198-201
- Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-6
- Sundt TM III, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-24
- Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-67
- Royston D. Intraoperative coronary thrombosis: can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994;8:137-41
- Royston D. Pro: aprotinin should be used in patients undergoing hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2001;15:121-5
- Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992;86:II410-412
- Alderman EL, Levy Hj, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998;116:716-30
- Westaby S. Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 2008;135:487-491
- Ehrlich M, Grabenwoger M, Cartes Zumelzu F, et al. Operations on the thoracic aorta and hypothermic circulatory arrest: is aprotinin safe? J Thorac Cardiovasc Surg 1998;115:220-5
- Mora Mangano CT, Neville MJ, Hsu PH, et al. Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest. Circulation 2001;104:I2786-1
- Mangano DT, Tudor JC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65
- Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006;46:327-38
- Augoustides J. Con: aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothor Vasc Anesth 2007;21:302-4
- Augoustides JG. Perioperative safety of aprotinin in coronary artery bypass graft surgery: is there life after BART? Drug Safety 2008;31:557-60
- Brown JR, Birkmeyer NJO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13
- Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886
- Augoustides JG, Fleisher LA. Comment on: Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials 2005;2:231-2
- Augoustides JG, Pochettino A, Ochroch EA, et al. Renal dysfunction after thoracic aortic surgery requiring deep hypothermic circulatory arrest: definition, incidence and clinical predictors. J Cardiovasc Anesth 2006;20:673-7
- Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008: 358: 784-793
- Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83
- Fergusson DA, Hebert PC, Mazer CD, et al. for the BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31
- Ray WA, Stein CM. The aprotinin story – is BART the final chapter? N Engl J Med 2008;358:2398-400
- Kluth M, Lueth JU, Zitterman A, et al. Safety of low-dose aprotinin in coronary artery bypass graft surgery: a single-centre investigation in 2436 patients in Germany. Drug Safety 2008;31:617-26
- Bosman M, Royston D. Aprotinin and renal dysfunction. Expert Opin Drug Saf 2008;7:663-77
- FDA clinical advisory on aprotinin. Available from: www.fda.gov [Last accessed 25 November 2008]
- Royston D. Aprotinin: an economy of truth. J Thorac Cardiovasc Surg 2008;136:798-99